Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development

While the current epigenetic drug development is still largely restricted to target DNA methylome, emerging evidence indicates that histone methylome is indeed another major epigenetic determinant for gene expression and frequently deregulated in acute myeloid leukaemia (AML). The recent advances in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, C T, So, C W E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378929/
https://www.ncbi.nlm.nih.gov/pubmed/27593928
http://dx.doi.org/10.1038/onc.2016.315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378929/
https://www.ncbi.nlm.nih.gov/pubmed/27593928
http://dx.doi.org/10.1038/onc.2016.315

Ejemplares similares